Expert review of pharmacoeconomics & outcomes research · 2025
The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kourlaba Georgia, Koutsis Georgios, Fakas Nikolaos, Tsimourtou Vana, Karachalios Georgios, Bakirtzis Christos, Grigoriadis Nikolaos
Аннотация
BACKGROUND: The review of healthcare costs in multiple sclerosis (MS) has been of increased interest. In this study, we aimed to estimate the economic burden of MS patients, treated with dimethyl fumarate (DMF) in Greece.
RESEARCH DESIGN AND METHODS: Four hundred and fifty-six participants were followed every 6 months after DMF initiation. Healthcare resource utilization, out-of-pocket expenses, and productivity loss data were recorded. Treatment cost and effectiveness of DMF were compared with those of previous treatments.
RESULTS: From a societal perspective, the total mean biennial burden was 13,113 € per patient, mainly attributed to direct healthcare costs (10,818 €, with medication accounting for almost 96%). From the payer perspective, the cost per patient was estimated at 10,462 €. The main driver of indirect cost was early retirement (87.8%). The treatment cost in the 2 years before the study was ~25% higher than the biennial DMF cost. A total of 43.9% of the patients experienced adverse events, mostly mild/moderate.
CONCLUSIONS: DMF displayed a societal cost mainly driven by medication, disease severity, disease duration and patients' age. There was evidence of beneficial effects on disease activity and quality of life with no new safety signals emerging.
TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (ID: NCT03101735).
RESEARCH DESIGN AND METHODS: Four hundred and fifty-six participants were followed every 6 months after DMF initiation. Healthcare resource utilization, out-of-pocket expenses, and productivity loss data were recorded. Treatment cost and effectiveness of DMF were compared with those of previous treatments.
RESULTS: From a societal perspective, the total mean biennial burden was 13,113 € per patient, mainly attributed to direct healthcare costs (10,818 €, with medication accounting for almost 96%). From the payer perspective, the cost per patient was estimated at 10,462 €. The main driver of indirect cost was early retirement (87.8%). The treatment cost in the 2 years before the study was ~25% higher than the biennial DMF cost. A total of 43.9% of the patients experienced adverse events, mostly mild/moderate.
CONCLUSIONS: DMF displayed a societal cost mainly driven by medication, disease severity, disease duration and patients' age. There was evidence of beneficial effects on disease activity and quality of life with no new safety signals emerging.
TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov (ID: NCT03101735).
Предметные рубрики MeSH
HumansDimethyl FumarateMultiple Sclerosis, Relapsing-RemittingGreeceFemaleMaleAdultMiddle AgedCost of IllnessTreatment OutcomeCost-Benefit AnalysisImmunosuppressive AgentsSeverity of Illness IndexHealth Care CostsPatient Acceptance of Health CareTime FactorsFollow-Up StudiesHealth ExpendituresAge FactorsYoung Adult